Amit Raval
Director, Real World Evidence Oncology Bayer
Seminars
Wednesday 28th October 2026
Panel Discussion: Breaking Down Organizational Silos Between Strategy, Science & Execution for RWE With AI
4:30 pm
- Why do AI‑driven RWE initiatives so often succeed technically but fail organizationally, and where do most companies get stuck?
- How can RWE/HEOR leaders better align data scientists, analysts, and medical experts around shared goals, methodologies, and accountability?
- What practical approaches are teams using to validate AI outputs without slowing delivery or undermining confidence in the evidence?
- How should organizations address cultural resistance and skills anxiety when AI drastically changes timelines, roles, and workflows?
- Who ultimately owns AI‑generated evidence and what governance models support innovation while protecting scientific and regulatory credibility?
Wednesday 28th October 2026
Current Status of RWD/E Use in Regulatory Decision Making: Lessons Learned, Ongoing Challenges, and Future Directions
1:30 pm
- Review FDA use cases where RWE has supported regulatory submissions and decisions
- Explore therapeutic-area differences in feasibility, fit-for-purpose data, and evidentiary expectations
- Discuss key challenges, lower hanging opportunities, and future directions for RWD/E in regulatory decision-making
